Journal of Pharmacological Sciences 131 (2016) 64–67

Contents lists available at ScienceDirect

Journal of Pharmacological Sciences

journal homepage: www.elsevier.com/locate/jphs

Short communication

P-glycoprotein inhibitors improve effective dose and time of pregabalin to inhibit intermittent cold stress-induced central pain

Takehiro Mukae [a], Wakako Fujita [b], Hiroshi Ueda [a, *]

[a] Department of Pharmacology and Therapeutic Innovation, Nagasaki University Graduate School of Biomedical Sciences, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan
[b] Department of Frontier Life Sciences, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8588, Japan

ARTICLE INFO

Article history:
Received 9 October 2015
Received in revised form
3 January 2016
Accepted 6 January 2016
Available online 14 January 2016

Keywords:
Pregabalin
Fibromyalgia
P-glycoprotein

ABSTRACT

Pregabalin (PGB) is a valuable therapeutic drug against chronic pain. Here we attempted to perform the combinatorial drug therapy with P-glycoprotein (P-gp) inhibitors to lower therapeutic dosage of PGB in the intermittent cold stress-induced fibromyalgia-like pain model. Single intracerebroventricular (i.c.v.) PGB injection exerted long-lasting anti-hyperalgesic effects for 72 h, while the effect of PGB given intraperitoneally (i.p.) disappeared within 3 h. Importantly, the pretreatment with P-gp inhibitors markedly prolonged the PGB (i.p.) effects, which lasted for 72 h. These results suggest that the combinatorial treatment with P-gp inhibitor enables the prolongation of dose-interval for PGB.

Pregabalin (PGB) is a central nervous system (CNS) targeting drug clinically used for epilepsy, trigeminal neuralgia, diabetic peripheral neuropathy and fibromyalgia (FM) (1, 2). High affinity and selective binding to voltage-gated calcium channels alpha2-delta (α2δ) subunits (3) is underlie the biological activity of PGB. Indeed PGB is known to modulate the voltage-dependent calcium channels gating dynamics and reduce calcium-dependent presynaptic release of neurotransmitters (4), leading to anti-hyperalgic or anti-allodynic actions (5). Although PGB is therapeutically valuable against neuropathic pain (NP) and FM, frequently observed side effects including peripheral edema limit their effective clinical use (6). Thus specific brain targeting or lowered therapeutic dosage is important therapeutic strategy with reduced adverse side effects.

CNS-partition of PGB is carefully regulated by influx and efflux transporters at blood–brain barrier (BBB) (7, 8). Especially, P-glycoprotein (P-gp), one of the ATP-binding cassette transporters is known to be involved (7). Here we investigated the effect of P-gp inhibitor on PGB-mediated anti-hyperalgesia and anti-allodynia phenotypes in intermittent cold stress (ICS)-induced FM-like pain model in mice.

Male C57BL/6J mice (TEXAM Corporation, Nagasaki, Japan) (20–25 g) were used. The mice were housed in a room (22 ± 3 °C) with free access to a standard laboratory diet and tap water. All procedures were approved by the Nagasaki University Animal Care Committee, and complied with the fundamental guidelines for the proper conduct of animal experiments and related activities in academic research institutions under the jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology, Japan.

Pregabalin was given by Pfizer (Ann Arbor, MI), while valspodar (Val) were purchased from Sigma–Aldrich Japan (Tokyo, Japan). These drugs were dissolved in physiological saline for intraperitoneal (i.p.) injection or in artificial cerebrospinal fluid (aCSF) for intrathecal (i.t.) and intracerebroventricular (i.c.v.) injection. Val was injected subcutaneously (s.c.) 0.5 h prior to PGB injection. The i.t. injection was given into the space between spinal L5 and L6 segments, according to the method described by Hylden and Wilcox (9).

Mice were exposed to intermittent cold stress (ICS), as previously described (10). We designated day 3 following the onset of the stress exposure as day 1 post-stress exposure (P1). Mice in the control group were maintained at 24 °C for all 3 days without any analgesics. Partial ligation of the sciatic nerve (SNL) was performed under pentobarbital (50 mg/kg) anesthesia, following the methods of Malmberg and Basbaum (11). The nociception test was performed 5 days after SNL.

In the thermal paw withdrawal tests, the nociception threshold was determined using thermal stimulator (IITC Inc., Woodland

* Corresponding author. Tel.: +81 95 819 2421; fax: +81 95 819 2420.
E-mail address: ueda@nagasaki-u.ac.jp (H. Ueda).
Peer review under responsibility of Japanese Pharmacological Society.

http://dx.doi.org/10.1016/j.jphs.2016.01.002

Hills, CA, USA) as previously described (12). A cut-off time of 20 s was set to avoid tissue damage. The mechanical paw pressure test was performed using a Transducer Indicator (Model 1601; IITC Inc.) as previously described (12). A cutoff pressure of 20 g was set to avoid tissue damage. ED50 was calculated based on the linear dose–response equation using 2 different dose/response points that include 50% maximum effect between them.

Statistical analyses were performed using one-way analysis of variance with the Tukey–Kramer multiple comparison *post-hoc* test. The criterion of significance was set at $p < 0.05$. All results are expressed as means ± standard error of the mean (SEM).

First we determined the anti-hyperalgesic effect of PGB in SNL model mice. As Fig. 1A shows, systemic PGB injection (30 mg/kg, i.p.) significantly inhibited the decrease in paw withdrawal latency (PWL) in SNL mice, indicating an anti-thermal hyperalgesic effect of PGB (i.p.). The effect of PGB (i.p.) was disappeared at 3 h after injection (Fig. 1A). Furthermore, PGB (i.p.) showed dose-dependent increase in the PWL in the dose range of 3–30 mg/kg (ED50 = 14.0 mg/kg). This corresponds with the previous report using other neuropathic pain model showing anti-cold allodynic effect of PGB (13). Similar effect was observed in the mechanical paw pressure test (Supplemental Fig. 1A). To determine the role of CNS in PGB effects, mice were injected with PGB (30 μg) via i.c.v. However, it did not show any effect (Fig. 1B). On the other hand, i.t. PGB (30 μg) showed significant anti-thermal hyperalgesic effect in SNL mice (Fig. 1C). The dose-dependent effect of PGB (i.t.) was also confirmed (ED50 = 1.8 μg).

Next we determined the anti-hyperalgesic effect of PGB in ICS model mice. As Fig. 1D shows, PGB injection (1 mg/kg, i.p.) significantly increased the PWL, indicating an anti-thermal hyperalgesic effect of PGB (i.p.) on ICS-induced FM-like pain. Furthermore, PGB (i.p.) showed dose-dependent increase in PWL in the dose range of 0.1–1 mg/kg (ED50 = 0.3 mg/kg). Similar results were obtained in mechanical paw pressure test (Supplemental Fig. 1B). To determine the role of CNS in PGB effect on ICS, mice were injected with PGB via i.c.v. at the dose of 1 μg. Pregabalin (i.c.v.) significantly increased the PWL in ICS exposed mice up to 72 h after injection (Fig. 1E). The dose-dependent effect of PGB (i.c.v.) was also confirmed in the dose range of 0.1–0.3 μg (ED50 = 0.2 μg). On the other hand, i.t. PGB (10 μg) showed significant effect only at 0.5 h after injection (Fig. 1F). The dose-dependent effect of PGB (i.t.) was also confirmed in the dose range of 1–10 μg (ED50 = 5.7 μg).

We have previously reported ICS exposure induces persistent hyperalgesia that last over 19 days after the stress (14). To determine the effect of PGB on ICS exposure-induced persistent hyperalgesia, mice were repeatedly injected with PGB (i.c.v.) at every 3 days starting on P5, and the effect of PGB was determined on the same days. As shown in Fig. 2A, on P5, PGB injection (i.c.v., 1 μg) significantly increased the PWL of ICS exposed mice up to 3 h in thermal paw withdrawal test. Similar effects were observed on P8 and P11. Importantly, PWL was gradually increased and completely returned to the normal (i.e., control mice) levels even after the cessation of repeated PGB (i.c.v.) injection (i.e., P14 to P20) (Fig. 2B). Similar results were obtained in the mechanical paw pressure test (Supplemental Fig. 2A). To determine whether the delivery of PGB to the brain is important for their therapeutic effects, we used specific inhibitor of P-gp, one of the ATP-binding cassette transporter that regulate effective CNS drug delivery at BBB. As P-gp inhibitors, we used Val, a Cyclosporine A-analog lacking immunosuppressant effects (28). In thermal paw withdrawal test, pretreatment of Val (3 mg/kg, s.c.) markedly prolonged the anti-thermal hyperalgesic effect of PGB (1 mg/kg, i.p.) up to 48 h after



Fig. 1. Blockade of ICS but not of SNL-induced hyperalgesia by supra-spinal PGB. Thermal hyperalgesia was determined by the measurement of PWL in SNL (A–C) or ICS (D–F) mice on 5 days (P5) after the onset of stress. The test was performed at the indicated periods after the i.p. (30 mg/kg) (A), i.c.v. (30 μg) (B), i.t. (30 μg) (C), i.p. (1 mg/kg) (D), i.c.v. (1 μg) (E) and i.t. (10 μg) (F) PGB injection. Data are expressed as means ± SEM. *$p < 0.05$, vs. Sham Veh (A–C) or Cont Veh (D–E); #$p < 0.05$, vs. Injury Veh (A–C) or ICS Veh (D–F).